Melissa Rewolinski Net Worth

The estimated Net Worth of Melissa Rewolinski is at least $220 Tausend dollars as of 14 September 2022. Melissa Rewolinski owns over 31,159 units of Lannett Co stock worth over $64,349 and over the last 4 years he sold LCI stock worth over $155,859. In addition, he makes $0 as Independent Director at Lannett Co.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Melissa Rewolinski LCI stock SEC Form 4 insiders trading

Melissa has made over 3 trades of the Lannett Co stock since 2020, according to the Form 4 filled with the SEC. Most recently he bought 31,159 units of LCI stock worth $15,268 on 14 September 2022.

The largest trade he's ever made was buying 31,159 units of Lannett Co stock on 14 September 2022 worth over $15,268. On average, Melissa trades about 10,093 units every 106 days since 2020. As of 14 September 2022 he still owns at least 93,259 units of Lannett Co stock.

You can see the complete history of Melissa Rewolinski stock trades at the bottom of the page.

Melissa Rewolinski biography

Dr. Melissa V. Rewolinski, Ph.D. is Independent Director of the Company. Dr. Rewolinski currently serves as principal of MVR Consulting, where she specializes in providing counsel to small and mid-size biotechnology and pharmaceutical companies. Earlier she held a number of senior level R&D positions for Intercept, rising to Senior Vice President, Head of Technical Operations, and member of the Executive Team. Previously, she served as Senior Director, Development for Amira Pharmaceuticals, and before that as a Chemical Development Group Leader and a Pharmaceutical Sciences Project Team Leader for Pfizer Global R&D. Dr. Rewolinski began her career at Pharmacia & Upjohn as a post-doctoral research scientist. Dr. Rewolinski earned a doctorate degree in organic chemistry and Bachelor of Science degree in chemistry, magna cum laude, from Rice University.

How old is Melissa Rewolinski?

Melissa Rewolinski is 49, he's been the Independent Director of Lannett Co since 2019. There are 16 older and 1 younger executives at Lannett Co. The oldest executive at Lannett Co., Inc. is Patrick LePore, 65, who is the Independent Chairman of the Board.

Insiders trading at Lannett Co

Over the last 22 years, insiders at Lannett Co have traded over $61,716,333 worth of Lannett Co stock and bought 6,036,340 units worth $16,940,403 . The most active insiders traders include William Farber, Jeffrey Farber und Patrick G Lepore. On average, Lannett Co executives and independent directors trade stock every 30 days with the average trade being worth of $39,386. The most recent stock trade was executed by John C Chapman on 17 November 2022, trading 20,000 units of LCI stock currently worth $10,200.

What does Lannett Co do?

Lannett Company, founded in 1942, develops, manufactures, packages, markets and distributes generic pharmaceutical products for a wide range of medical indications.

Complete history of Melissa Rewolinski stock trades at Arbutus Biopharma Corp und Lannett Co

Lannett Co executives and stock owners

Lannett Co executives and other stock owners filed with the SEC include:

• Timothy Crew,
  Chief Executive Officer, Director
• Samuel Israel,
  General Counsel, Chief Legal Officer
• Timothy C. Crew,
  CEO & Director
• John Kozlowski,
  Chief Financial Officer, Principal Accounting Officer, Vice President - Finance
• John Abt,
  Vice President and Chief Quality and Operations Officer
• Maureen M. Cavanaugh,
  Sr. VP & Chief Commercial Operations Officer
• John Kozlowski,
  VP of Fin., CFO & Principal Accounting Officer
• Samuel H. Israel,
  Gen. Counsel & Chief Legal Officer
• John M. Abt,
  VP and Chief Quality & Operations Officer
• Robert Ehlinger,
  Vice President - Logistics, Chief Information Officer
• David Drabik,
  Independent Director
• Patrick LePore,
  Independent Chairman of the Board
• Paul Taveira,
  Independent Director
• Albert Paonessa,
  Director
• Jeffrey Farber,
  Director
• John Chapman,
  Independent Director
• Melissa Rewolinski,
  Independent Director
• Maureen Cavanaugh,
  Senior Vice President and Chief Commercial Operations Officer
• Grant Brock,
  VP of Operations
• Kristie Stephens,
  Chief Compliance Officer & VP of Regulatory Affairs
• Robert Ehlinger,
  VP & Chief Information Officer
• Arthur P Bedrosian,
  President
• G. Michael Landis,
  Principal Accounting Officer
• David Farber,
  Treasurer
• Mahendra Dedhiya,
  Chief Scientific Affairs
• James M. Maher,
  Director
• Keith Richard Ruck,
  Interim CFO
• Kevin Smith,
  
• Bernard Sandiford,
  
• Marvin Novick,
  Director
• Properties Group, Llc Farber,
  10% owner
• Michael Bogda,
  President
• William Schreck,
  VP, Logistics
• Ernest Sabo,
  VP, Corporate Compliance
• Kenneth Sinclair,
  Director
• Ronald A West,
  Director
• William Farber,
  Chief Executive Officer
• Albert I Wertheimer,
  Director
• Myron D Winkelman,
  Director
• Martin P Galvan,
  Former VP of Finance & CFO